Clinical Trials
2,159 trialsNCT01135329 2026-05-27
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03237377 2026-05-27
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03765983 2026-05-27
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05712356 2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Terminated
NCT02316548 2026-05-22
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NRG Oncology
Phase 2 Terminated
NCT03646461 2026-05-22
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
Phase 2 Terminated
NCT04169074 2026-05-22
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
University of Arizona
Phase 2 Terminated
NCT01885949 2026-05-20
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT04438382 2026-05-15
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT04716725 2026-05-15
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT05846659 2026-05-15
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT03246906 2026-05-14
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT04030559 2026-05-14
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
University of California, Davis
Phase 2 Terminated
NCT05085002 2026-05-14
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT04221438 2026-05-12
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT04668833 2026-05-07
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05027425 2026-05-06
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
University of Cincinnati
Phase 2 Terminated
NCT03506373 2026-05-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT04034251 2026-05-05
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04786093 2026-05-05
Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT05144529 2026-05-05
TOP2101
Duke University
Phase 2 Terminated
NCT04631744 2026-05-01
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Terminated
NCT04639024 2026-05-01
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Duke University
Phase 2 Terminated
NCT03799445 2026-04-30
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05156125 2026-04-30
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Oppilan Pharma Ltd
Phase 2 Terminated
NCT06630325 2026-04-28
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT05581589 2026-04-27
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
University of Washington
Phase 2 Terminated
NCT03622775 2026-04-24
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05090566 2026-04-24
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Terminated
NCT01472445 2026-04-23
Vitamin D and Breast Cancer: Does Weight Make a Difference?
Stanford University
Phase 2 Terminated
NCT02562625 2026-04-23
PERM
Royal Marsden NHS Foundation Trust
Phase 2 Terminated
NCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02874430 2026-04-22
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT05498220 2026-04-16
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT03856216 2026-04-15
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05879185 2026-04-13
A Study of XmAb23104 in People With Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT05567835 2026-04-09
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT05744375 2026-04-02
TRANSCENDER
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT03150004 2026-03-30
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
Phase 2 Terminated
NCT03386357 2026-03-27
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Phase 2 Terminated
NCT05036681 2026-03-27
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01743950 2026-03-25
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
Phase 2 Terminated
NCT01453088 2026-03-24
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Hackensack Meridian Health
Phase 2 Terminated
NCT05059470 2026-03-23
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
NCT04676360 2026-03-13
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT04796324 2026-03-12
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
Allarity Therapeutics
Phase 2 Terminated
NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
NCT04832854 2026-03-11
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated